fbpx

Learn more about the device that is revolutionizing skin cancer detection

Complete this form and a representative will contact you about making DermaSensor your new assistant for skin cancer care.

  • Provide your information above to be contacted by a DermaSensor rep.
  • This field is for validation purposes and should be left unchanged.

Make DermaSensor™ Your New Assistant For Skin Cancer Care

We’ve launched the world’s first point-and-click device that brings objective skin cancer assessment to primary care offices. You now have a tool to help evaluate patient skin cancer risk in just seconds.
  • Rapid, non-invasive skin cancer assessment by any trained team member
  • Objective result can improve your clinical decisions and confidence
  • Improve your skin cancer detection by 13% as demonstrated in a study with 57 GPs
  • Can help avoid benign excisions with unnecessary morbidity and poor reimbursement

Explore the device that simplifies skin cancer evaluation

Get started for free
Rapid Recording

Rapid Recording

Quick, point-and-click recordings collect and analyze non-visual spectral data quickly

Optical Spectroscopy

Optical Spectroscopy

Light-emitting tip non-invasively scans the lesion, receiving and analyzing spectral data at the cellular level from below the skin's surface

Easy to Use

Easy to Use

Wireless, ergonomic design makes the device intuitive to learn and easy to use

Risk Assessment

Immediate Result

DermaSensor's proprietary algorithm provides an instant, objective result to support your clinical decision at the point of care

DermaSensor May Help You To:

  • Make better and more confident decisions
  • Detect 93% of skin cancer while avoiding up to 37% of benign excisions which have unnecessary morbidity
  • Augment your typical skin assessment routine and increase your reimbursement level
  • Increase revenue by introducing a value-based skin health service with out of pocket contributions by patients
  • Improve your practice’s image by incorporating new and innovative technology

Get the tools you need without the expense. Our pay-as-you-go model means you pay as low as $7/lesion + GST to assess skin lesions in a matter of seconds after your one-time activation fee of $399 + GST.

Lease Now

Assess

Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.

Analyze

Use DermaSensor to analyze those lesions of concern to receive a Higher Risk or Lower Risk result for each lesion

Act

Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.

Simple Design.
Effortless Application

  • Intuitive on-screen user interface guides you step-by-step through the evaluation
  • Activate a recording using either the touch-screen interface or conveniently positioned side buttons

DermaSensor is not a camera or dermatoscope. DermaSensor uses pulses of light and elastic scattering spectroscopy to assess a lesion’s cellular and sub-cellular structures.

Ready to learn more?

Safety and Efficacy Results for DERM-ASSESS II Prospective, Multi-Centre Study

Study reported no adverse events as well as no significant difference between DermaSensor's and dermatologists' sensitivity and specificity

DermaSensor's sensitivity for melanoma was 100.0%* while the study dermatologists' was 90.9%. For BCC and SCC, also known as Non-Melanoma Skin Cancer (NMSC), DermaSensor's sensitivity was 93.3% and the dermatologists' was 98.3%

DermaSensor Device and Dermatologist Sensitivity For Skin Cancers
100
90
80
70
60
50
40
30
20
10
0
Overall Sensitivity
Melanoma Sensitivity
NMSC Sensitivity
DermaSensor Device
Dermatologist In-Person Assessment
94%
Skin cancer detection results improved from 81% to 94% with use of the DermaSensor device.
100%
DermaSensor's spectroscopy technology showed a 100% sensitivity for melanoma in two multi-year, multi-site prospective studies.
Risks
False-positive and false-negative results may lead to unnecessary care or to a malignant skin lesion not being optimally managed, respectively. However, it is important to note that biopsy is used to confirm pathology and that elastic scattering spectroscopy is to be used as an adjunctive tool to visual inspection and history-taking. See all Claims and Substantiations

©2021 DermaSensor, inc

Scroll to Top